-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Maintains Overweight on Kymera Therapeutics, Raises Price Target to $110

Benzinga·12/11/2025 13:52:40
語音播報
Stephens & Co. analyst Sudan Loganathan maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $65 to $110.